📣 VC round data is live. Check it out!

APT Medical Valuation Multiples

Discover revenue and EBITDA valuation multiples for APT Medical and similar public comparables like BillionToOne, Mirion, Imeik Technology Development, Cochlear and more.

APT Medical Overview

About APT Medical

APT Medical Inc is engaged in the research and development, production and sales of electrophysiological and vascular interventional medical devices for cardiovascular and cerebrovascular diseases. Its products are sold in Europe, Eastern Europe, Southeast Asia and other countries and other regions.


Founded

2002

HQ

China

Employees

N/A

Website

aptmed.com

Financials (LTM)

Revenue: $419M
EBITDA: $167M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

APT Medical Financials

APT Medical reported last 12-month revenue of $419M and EBITDA of $167M.

In the same LTM period, APT Medical generated $306M in gross profit, $167M in EBITDA, and $133M in net income.

Revenue (LTM)


APT Medical P&L

In the most recent fiscal year, APT Medical reported revenue of $382M and EBITDA of $155M.

APT Medical is profitable as of last fiscal year, with gross margin of 73%, EBITDA margin of 41%, and net margin of 32%.

See analyst estimates for APT Medical
LTMLast FY202320242025202620272028
Revenue$419M$382M$244M$305M$382M
Gross Profit$306M$278M$174M$221M$278M
Gross Margin73%73%71%72%73%
EBITDA$167M$155M$98M$123M$155M
EBITDA Margin40%41%40%40%41%
EBIT Margin36%37%35%37%37%
Net Profit$133M$121M$79M$100M$121M
Net Margin32%32%32%33%32%

Financial data powered by Morningstar, Inc.

APT Medical Stock Performance

APT Medical has current market cap of $4B, and enterprise value of $4B.

Market Cap Evolution


APT Medical's stock price is $30.85.

APT Medical share price increased by 1.7% in the last 30 days, and decreased by 28.5% in the last year.

APT Medical has an EPS (earnings per share) of $0.86.

See more trading valuation data for APT Medical
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$4B2.0%1.7%-15.9%-28.5%$0.86

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

APT Medical Valuation Multiples

APT Medical trades at 9.9x EV/Revenue multiple, and 25.0x EV/EBITDA.

See NTM and 2027E valuation multiples for APT Medical

EV / Revenue (LTM)


APT Medical Financial Valuation Multiples

As of June 4, 2026, APT Medical has market cap of $4B and EV of $4B.

APT Medical has a P/E ratio of 32.7x.

LTMLast FY202320242025202620272028
EV/Revenue9.9x10.9x17.1x13.6x10.9x
EV/EBITDA25.0x26.8x42.3x33.7x26.8x
EV/EBIT27.6x29.8x48.8x37.3x29.8x
EV/Gross Profit13.6x15.0x23.9x18.8x15.0x
P/E32.7x35.9x55.1x43.7x35.9x
EV/FCF43.8x41.3x57.8xn/m41.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified APT Medical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

APT Medical Margins & Growth Rates

APT Medical grew revenue by 26% and EBITDA by 23% in the last fiscal year.

In the most recent fiscal year, APT Medical reported gross margin of 73%, EBITDA margin of 41%, and net margin of 32%.

See estimated margins and future growth rates for APT Medical

APT Medical Margins

Last FY202420252026202720282029
Gross Margin73%72%73%73%
EBITDA Margin41%40%41%40%
EBIT Margin37%37%37%36%
Net Margin32%33%32%32%
FCF Margin26%5%26%20%

APT Medical Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth26%25%25%26%
Gross Profit Growth26%27%26%26%
EBITDA Growth23%26%26%23%
EBIT Growth23%31%25%23%
Net Profit Growth26%26%22%26%
FCF Growth(4%)(81%)632%(4%)

Data powered by FactSet, Inc. and Morningstar, Inc.

APT Medical Operational KPIs

APT Medical's Rule of 40 is 65% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

APT Medical's Rule of X is 104% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for APT Medical
LTMLast FY202320242025202620272028
Rule of 4066%65%---
Bessemer Rule of X106%104%---
S&M Expenses to Revenue18%17%8%8%7%
G&A Expenses to Revenue5%5%2%1%2%
R&D Expenses to Revenue14%14%14%14%14%
Opex to Revenue-36%36%36%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

APT Medical Competitors

APT Medical competitors include BillionToOne, Mirion, Imeik Technology Development, Cochlear, Rigaku, Caris Life Sciences, LivaNova, Jiangsu Yuyue Medical, Canon Marketing Japan and Ottobock.

Most APT Medical public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
BillionToOne12.9x10.7x105.5x67.9x
Mirion5.7x5.2x23.0x20.6x
Imeik Technology Development11.0x10.6x17.1x17.8x
Cochlear2.7x2.7x10.3x13.0x
Rigaku7.9x7.7x34.1x32.2x
Caris Life Sciences5.3x4.8x31.0x29.5x
LivaNova2.8x2.7x12.1x11.6x
Jiangsu Yuyue Medical3.3x3.2x13.3x16.2x

This data is available for Pro users. Sign up to see all APT Medical competitors and their valuation data.

Start Free Trial

APT Medical VC Funding History

Before going public, APT Medical raised $61M in total equity funding, across 4 rounds.

Last private valuation of APT Medical was $87M, after raising $4M in October 2016 from Qiming Venture Partners.


APT Medical Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-19Undisclosed stageQiming Venture Partners$27M-APT Medical is a Chinese medical device company founded in 2002, specializing in coronary artery access and electrophysiological medical devices, peripheral blood vessels, and nerve intervention devices. It holds a leading position in the domestic China market, ranking No.1 in market share for electrophysiological medical devices and No.3 for coronary artery medical devices in 2019 by sales amount per Frost & Sullivan. Qiming Venture Partners participated as an A round investor and became the largest institutional shareholder, owning 19.35% post-IPO. The company successfully listed on the Shanghai Stock Exchange STAR Board on January 7, 2021, at an issue price of CNY 74.46 per share, opening at CNY 221.73 and closing at CNY 257.02, achieving a market cap of CNY 17.14 billion (USD 2.65 billion).
Nov-18Series CQiming Venture Partners$19M-APT Medical is a Chinese medical device company founded in 2002, specializing in coronary artery access and electrophysiological medical devices, peripheral blood vessels, and nerve intervention products. It holds leading market positions in China, ranking No.1 in domestic electrophysiological medical devices and No.3 in coronary artery medical devices by sales amount in 2019 per Frost & Sullivan. Qiming Venture Partners participated as an A round investor and became the largest institutional shareholder, owning 19.35% post-IPO in 2021. APT Medical listed on the Shanghai Stock Exchange STAR Board on January 7, 2021, at an issue price of CNY 74.46 per share, opening at CNY 221.73 and closing at CNY 257.02, achieving a market cap of CNY 17.14 billion (USD 2.65 billion). Post-listing, APT Medical expanded internationally while maintaining domestic leadership in its segments.
Aug-18Series BQiming Venture Partners$11M--
Oct-16Series AQiming Venture Partners$4M$87MAPT Medical, founded in 2002, is a Chinese medical device company specializing in coronary artery access, electrophysiological devices, and peripheral blood vessel and nerve intervention solutions. The company is the domestic leader in China's medical device market, ranking number one in electrophysiological medical devices market share and third in coronary artery devices as of 2019. Qiming Venture Partners invested approximately CNY 120 million in APT Medical's B round financing in 2016, at a post-investment valuation of approximately CNY 600 million. This represented Qiming's second investment in the company, having first backed APT Medical in 2014 at a CNY 800 million valuation. APT Medical subsequently went public on the Shanghai Stock Exchange's STAR Board in January 2021 at an IPO price of CNY 74.46 per share, with closing market cap of CNY 17.14 billion (USD 2.65 billion). Qiming's investment delivered a 16.8x return when the firm exited its stake in January 2023, as Shenzhen Mindray Bio-Medical Electronics acquired a 24.61% stake in APT Medical for CNY 6.652 billion.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About APT Medical

When was APT Medical founded?APT Medical was founded in 2002.
Where is APT Medical headquartered?APT Medical is headquartered in China.
Is APT Medical publicly listed?Yes, APT Medical is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of APT Medical?APT Medical trades under 688617 ticker.
When did APT Medical go public?APT Medical went public in 2021.
Who are competitors of APT Medical?APT Medical main competitors include BillionToOne, Mirion, Imeik Technology Development, Cochlear, Rigaku, Caris Life Sciences, LivaNova, Jiangsu Yuyue Medical, Canon Marketing Japan, Ottobock.
What is the current market cap of APT Medical?APT Medical's current market cap is $4B.
What is the current revenue of APT Medical?APT Medical's last 12 months revenue is $419M.
What is the current revenue growth of APT Medical?APT Medical revenue growth (NTM/LTM) is 27%.
What is the current EV/Revenue multiple of APT Medical?Current revenue multiple of APT Medical is 9.9x.
What is the current EBITDA of APT Medical?APT Medical's last 12 months EBITDA is $167M.
What is APT Medical's EBITDA margin?APT Medical's last 12 months EBITDA margin is 40%.
What is the current EV/EBITDA multiple of APT Medical?Current EBITDA multiple of APT Medical is 25.0x.
What is the current FCF of APT Medical?APT Medical's last 12 months FCF is $95M.
What is APT Medical's FCF margin?APT Medical's last 12 months FCF margin is 23%.
What is the current EV/FCF multiple of APT Medical?Current FCF multiple of APT Medical is 43.8x.
How many companies APT Medical has acquired to date?APT Medical hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies APT Medical has invested to date?APT Medical hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to APT Medical

Lists including APT Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial